Quince Therapeutics, Inc. (QNCX) – What Are Investment Firms Saying About This Stock?

Shares of Quince Therapeutics, Inc. (NASDAQ:QNCX – Get Free Report) have been given a consensus rating of “Moderate Buy” by the fourteen ratings firms that are presently covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation, seven have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $189.88.

A number of analysts have recently issued reports on QNCX shares. Craig Hallum upgraded shares of Quince Therapeutics to a “strong-buy” rating in a report on Thursday, August 27th. Zacks Research raised shares of Quince Therapeutics to a “hold” rating in a research note on Thursday, October 1st. Citigroup restated a “market outperform” rating on shares of Quince Therapeutics in a research note on Tuesday, September 29th. Citizens Jmp raised Quince Therapeutics from a “market perform” rating to an “outperform” rating and set a $77.00 price objective for the company in a research note on Tuesday, September 22nd. Finally, Wall Street Zen downgraded Quince Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 22nd.

Check Out Our Latest Stock Report on Quince Therapeutics

Institutional Trading of Quince Therapeutics

A hedge fund recently bought a new position in Quince Therapeutics stock. BlackRock Inc. acquired a new position in shares of Quince Therapeutics, Inc. (NASDAQ:QNCX – Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 1,702 shares of the company’s stock, valued at approximately $31,000. BlackRock Inc. owned approximately 0.17% of Quince Therapeutics as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 30.75% of the company’s stock.

Quince Therapeutics Price Performance

Shares of QNCX remained flat at $31.73 during midday trading on Friday. Quince Therapeutics has a twelve month low of $15.10 and a twelve month high of $909.98. The stock has a market capitalization of $32.27 million, a price-to-earnings ratio of -0.20 and a beta of 1.33. The stock has a fifty day simple moving average of $30.64 and a 200 day simple moving average of $30.00.

Quince Therapeutics (NASDAQ:QNCX – Get Free Report) last issued its earnings results on Friday, August 14th. The company reported ($12.31) EPS for the quarter, topping analysts’ consensus estimates of ($28.02) by $15.71. As a group, equities analysts forecast that Quince Therapeutics will post -8.39 EPS for the current year.

About Quince Therapeutics

(Get Free Report)

Quince Therapeutics is a biotechnology company focused on developing treatments for rare diseases. Its principal program has been EryDex, an investigational therapy designed to deliver dexamethasone sodium phosphate inside a patient’s own red blood cells. The company developed EryDex for ataxia-telangiectasia, a rare inherited disorder that can cause progressive neurological and immune-system problems. The treatment uses a process intended to load the drug into red blood cells for gradual release.

Further Reading

Analyst Recommendations for Quince Therapeutics (NASDAQ:QNCX)

Receive News & Ratings for Quince Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quince Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.